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Although family history is awell-established risk factor for Parkinson’s disease (PD), fewer than 5%of PD cases
can be attributed to known genetic mutations. The etiology for the remainder of PD cases is unclear; however,
neuronal accumulation of the protein a-synuclein is common to nearly all patients, implicating pathways that
influence a-synuclein in PD pathogenesis. We report a genome-wide significant association (P 5 3.97 3 1028)
between a polymorphism, rs1564282, in the cyclin-G-associated kinase (GAK) gene and increased PD risk, with
a meta-analysis odds ratio of 1.48. This association result is based on the meta-analysis of three publicly
available PD case–control genome-wide association study and genotyping from a new, independent Italian
cohort. Microarray expression analysis of post-mortem frontal cortex fromPDand control brains demonstrates
a significant association between rs1564282 and higher a-synuclein expression, a known cause of early onset
PD. Functional knockdown of GAK in cell culture causes a significant increase in toxicity when a-synuclein
is over-expressed. Furthermore, knockdown of GAK in rat primary neurons expressing the A53T mutation of
a-synuclein, a well-established model for PD, decreases cell viability. These observations provide evidence
that GAK is associated with PD risk and suggest that GAK and a-synuclein interact in a pathway involved in
PD pathogenesis. The GAK protein, a serine/threonine kinase, belongs to a family of proteins commonly
targeted for drug development. This, combined with GAK’s observed relationship to the levels of a-synuclein
expression and toxicity, suggests that the protein is an attractive therapeutic target for the treatment of PD.
INTRODUCTION
Parkinson’s disease (PD) is the second most common neurode-
generative disorder, trailing only Alzheimer’s disease in
prevalence. PD presents clinically with resting tremor, muscu-
lar rigidity and bradykinesia (1). Pathologically, the disease is
characterized by the loss of dopaminergic neurons within the
substantia nigra pars compacta and the presence of Lewy
bodies (2). These hallmark intraneuronal inclusions are
primarily composed of the small, lipid binding protein
a-synuclein (3). Although a critical role for a-synuclein in
PD pathogenesis is universally accepted, ,5% of all PD
cases can be attributed to genetic mutations in a-synuclein
and the other known PD genes.
While .95% of PD cases are considered idiopathic, it is
well established that between 16 and 27.5% have a positive
family history and first-degree relatives of PD patients
have a substantially increased risk for PD compared with
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first-degree relatives of controls (4–6). These observations led
us to undertake the GenePD Study, an evaluation of familial
PD cases aimed at identifying genes that influence PD suscep-
tibility. The GenePD Study, in collaboration with the
PROGENI Study, performed a genome-wide association
study (GWAS) (dbGaP Accession: phs000126.v1.p1) focusing
on families with multiple affected relatives (7). This was the
first GWAS to implicate non-coding single nucleotide poly-
morphisms (SNPs) within the genes encoding a-synuclein
(SNCA) and the micro-tubule-associated protein tau (MAPT)
in PD risk (7). Both findings were confirmed in the subsequent
GWAS of idiopathic PD (8,9).
We hypothesized that our familial PD cohort (7) was posi-
tioned to identify genes that GWAS of primarily idiopathic PD
failed to detect (8–12). The region producing the strongest
P-value for familial PD risk included the cyclin-G-associated
kinase (GAK) gene with a minor allele conferring a 1.7 odds
ratio (OR) for PD, which, although suggestive, failed to
reach the conservative level for genome-wide significance at
P, 5.0 × 1028 (13). Recently, Hamza et al. (14) performed
a PD GWAS in 2000 cases and 1986 controls, and in a
meta-analysis with our study (7), the GAK region reached
genome-wide significance (P ¼ 3.2× 1029). GAK was
shown previously to be among 137 genes differentially
expressed in the substantia nigra pars compacta of PD
patients when compared with controls, with a 1.56-fold
change (15). The combination of these independent findings
prompted our further investigation of the involvement of
GAK in PD pathogenesis.
GAK is a ubiquitously expressed protein (16), containing
highly conserved serine/threonine kinase (17,18), PTEN
(19,20) and J-domains (17,21). Interestingly, the clathrin-
binding C-terminal domain of GAK has been shown to bind
pre-cathepsin D (CTSD) and to directly sort the zymogen
into clathrin-coated vesicles destined for the lysosome (22).
Recently, CTSD was implicated as the main lysosomal
enzyme involved in a-synuclein degradation (23–25).
Mutations in CTSD have been shown to induce the pathologi-
cal accumulation of a-synuclein in mice, sheep and human
infants afflicted with fatal CTSD-deficient forms of neuronal
ceroid lipofuscinosis (OMIM #610127) (24,25). Together,
these findings led us to investigate the interrelationships
between GAK, SNCA and CTSD and their potential role in a
previously undescribed pathway for PD pathogenesis. Here
we report compelling evidence for interactions between GAK,
SNCA and CTSD as well as biological evidence that reduced
GAK function enhances a-synuclein-mediated toxicity.
RESULTS
To substantiate the association between the GAK SNP
rs1564282 and increased PD risk, we performed a
meta-analysis of three publicly available PD case–control
GWAS, combined with our genotyping of a new, independent
sample of 862 Italian PD cases and 517 controls. We used P ≤
5 × 1028 as the threshold for genome-wide significance, a
widely accepted threshold based on correction for 1 million
independent variants in the genome (13). Our results confirm
that the minor allele of the GAK SNP rs1564282 is associated
with a 1.48 increased odds of PD at a genome-wide level of
significance (P ¼ 3.97 × 1028; Table 1). While all four
studies independently show increased risk of PD associated
with this SNP, the largest effect size is observed in the familial
PD cohort. Interestingly, restricting analysis of the new Italian
cases to those with reported family history (n ¼ 165) shows a
stronger effect size (OR ¼ 1.9) and a stronger P-value (P ¼
0.0026) than the idiopathic cases alone (OR ¼ 1.2, P ¼
0.18), emphasizing the advantages of focusing on familial
cases in the search for genetic contributors to PD.
As reviewed above, SNCA, GAK and CTSD appear to inter-
act either directly or indirectly. To evaluate whether there is a
correlation between the expression of these genes, as reflected
by messenger ribonucleic acid (mRNA) levels, in control or
PD brains, we analyzed four probes (one each for exons 26
and 28 of GAK, one for the 3′-UTR of SNCA, and one for
exon 6 of CTSD) present on a commercially available micro-
array (One-Color Agilent 60-mer Whole Human Genome
Microarray). We screened the microarray with total RNA pur-
ified from frontal cortex of 33 PD cases and 29 controls (see
Table 2 for characteristics of samples). Despite the expression
levels of the two C-terminal GAK probes showing marked cor-
relation with one another in both PD (r2 ¼ 0.8) and controls
(r2 ¼ 0.6), the expression of GAK exon 26, but not exon 28,
was observed to have a positive correlation with expression
of CTSD exon 6 in both PD and control brains (r2 ¼ 0.5)
(Table 3). Neither GAK nor CTSD expression was correlated
with total SNCA expression in either PD or control brains.
We also used the microarray data from these four probes to
analyze the relationship between several SNPs and expression
levels of GAK, CTSD and SNCA, adjusting for PD/control
status, RNA integrity number (RIN), post-mortem interval
(PMI) and age at death (Table 4). In addition to the GAK
SNP rs1564282, we evaluated three SNPs located within 100
000 bp of SNCA, which were also implicated in PD risk in
our familial GWAS (7). In order to account for the 16 different
association tests (four SNPs and four expression probes) that
were conducted, we used an adjusted alpha-level of signifi-
cance of 0.007; this value was determined by applying a modi-
fied Bonferroni correction (26) that accounts for the high
degree of correlation between the expression levels of the
used probes (mean R2 ¼ 0.3). We found that rs1564282 in
GAK associated significantly with higher levels of total
SNCA expression (P ¼ 0.003). Additionally, an intronic
SNCA SNP (rs356188) with a minor allele conferring a protec-
tive effect in the GWAS (7) was significantly associated with
higher CTSD levels (P ¼ 0.007). Some suggestive associations
were also detected: rs1564282 GAK with lower levels of GAK
exon 28 (P ¼ 0.03), and rs356188 with higher levels of GAK
exon 26 (P ¼ 0.02). None of the SNPs within the SNCA gene
region was significantly associated with SNCA expression
levels (Table 4).
Previous reports have demonstrated that reduced expression
of CTSD results in increased a-synuclein aggregation and tox-
icity (24,25), and that RNAi targeting of GAK in mammalian
cell culture reduces CTSD protein levels in the lysosome (22).
We decided to define the connection between GAK and
a-synuclein by evaluating whether manipulating GAK
expression affects a-synuclein-mediated toxicity and
a-synuclein protein levels in a simple mammalian cell
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culture system. We performed siRNA knockdown of GAK in
HEK 293 cells while overexpressing a-synuclein. Reducing
GAK expression consistently increased toxicity in
a-synuclein-overexpressing cells, as indicated by increased
adenylate kinase release (Fig. 1A). Notably, knockdown of
GAK had no effect on toxicity in the absence of a-synuclein
overexpression, as demonstrated by the green fluorescent
protein (GFP) overexpression control (Fig. 1A). Western
blot analysis confirmed that GAK siRNA treatment dramati-
cally suppressed GAK protein levels in these cells (Fig. 2A).
ELISA revealed that this reduction in the GAK protein was
accompanied by a significant increase in a-synuclein protein
levels in a-synuclein-overexpressing cells (Fig. 1B), although
the less-sensitive western blot analysis demonstrated only
subtle changes in a-synuclein protein levels (Fig. 2B).
Control siRNA had no effect on a-synuclein levels and GAK
siRNA did not induce a-synuclein expression when GFP
was overexpressed instead of a-synuclein (Fig. 1B). These
cell culture results suggest a synergistic effect whereby an
increase in a-synuclein combined with a decrease in GAK
results in increased cytotoxicity.
We also investigated whether the interaction of SNCA and
GAK was present for the A53T mutation in a-synuclein. In
this experiment, we examined how the reduction in endogen-
ous GAK influences a-synuclein-mediated toxicity in cultured
primary rat midbrain neurons expressing the A53T form of
a-synuclein, an in vitro model of PD (27–31). Primary rat
midbrain neuron cultures consist of 4–5% tyrosine
hydroxylase positive (TH+) cells, which have been described
as being exquisitely sensitive to a-synuclein levels in PD (31).
Primary rat midbrain cultures were treated with sub-lethal
levels of an adenovirus containing the A53T-SNCA variant
associated with early onset PD, with or without lentiviruses
encoding one of two GAK-specific short-hairpin RNAs
(shRNAs) (each targeting a different coding region of rat
GAK). Ninety-six hours after transduction, we assessed
relative dopaminergic cell viability by immunocytochemistry
for TH, a marker of dopaminergic neurons and
microtubule-associated protein 2 (MAP2), a general neuronal
marker. Transduction with the A53T-SNCA virus or with
either GAK shRNA virus alone did not affect dopaminergic
cell viability compared with untransduced cultures.
However, simultaneous exposure to the A53T-a-synuclein
adenovirus and either of the GAK-specific shRNA lentiviruses
dramatically reduced the number of TH+ neurons relative to
MAP2+ neurons, suggesting that a-synuclein neurotoxicity is
triggered or enhanced by the combination of overexpression of
mutant SNCA and reduction in GAK (Fig. 1C and D). In other
(control) experiments, we found that a non-specific lentivirus
(lenti-LacZ) failed to exacerbate dopaminergic cell death eli-
cited by the A53T adenovirus (Strathearn and Rochet, data
not shown). To confirm that transduction with the GAK
shRNA lentiviruses reduces GAK protein levels, we examined
GAK expression in MES23.5 dopaminergic cells by immuno-
blot analysis and found that each of the shRNAs reduced GAK
protein levels by 90–95% relative to control and 80–90%
relative to cells expression A53T a-synuclein (Fig. 2C).
These results are compatible with those obtained for the
HEK 293 cells, indicating that GAK reduction plays an impor-
tant role in cell toxicity not only when a-synuclein is over-
expressed, but also for A53T mutant-a-synuclein.
DISCUSSION
Emerging evidence implicates endocytic pathways in the
pathogenesis of the most common neurodegenerative dis-
orders. Highlighting this concept are the results from a
recent Alzheimer’s disease GWAS implicating PICALM
(32), a gene involved in clathrin-mediated endocytosis. In
PD, the relationship between disrupted endocytic trafficking
and a-synuclein accumulation has received increasing atten-
tion in a diverse number of models for the disorder
(30,33,34). Notably, GAK (also known as auxilin-2) and
PICALM have similar canonical interactions with clathrin
(16,17,19,21,35) and both proteins are critical to clathrin-
mediated endocytosis (36). Here we report that a SNP in the
GAK gene (rs1564282), previously implicated as the top hit
in a GWAS for familial PD (7), is significantly associated
with PD risk at a genome-wide level of significance (P ¼
3.97 × 1028). These results position GAK alongside SNCA
and MAPT as a PD risk-associated gene, and also implicate
clathrin-mediated endocytosis in the etiology of PD.
Identification of the GAK gene in a GWAS of strictly famil-
ial PD supports the importance of studying PD cohorts
enriched for family history of disease. The Italian sample
studied for replication had detailed data on family history,
allowing us to observe the enhanced effect and improved
P-value among those cases with family history of PD.
Hamza et al. (14) recently confirmed our association with
Table 1. Meta-analysis of three publicly available GWAS and replication genotyping
SNP Familial PD GWAS7 1st NIA PD-GWAS10 2nd NIA PD-GWAS9 Milan, Italy cohort Meta-analysis
n OR P-value n OR P-value n OR P-value n OR P-value OR P-value
rs1564282 1728 1.70 5.9 × 1026 505 1.55 0.047 1166 1.34 0.033 1379 1.32 0.0497 1.48 3.97 × 1028a
Each OR reflects the effect of the minor (T) allele, which has a frequency of 11% in the overall sample.
aAchieves genome-wide significance.
Table 2. Characteristics of RNA samples for microarray analysis
Sample type
(n)
Age at death,
years (range)
PMI, hours
(range)
RIN (range) Tissue pHa
(range)
Control (29) 75.21
(58–97)
13.70
(1.50–39.67)
7.36
(4.8–8.5)
6.641
(6.26–7.32)
PD (33) 77.67
(64–94)
7.43
(1.16–30.75)
7.182
(5.2–8.4)
6.652
(6.27–7.13)
aThe pH was measured following a previously established protocol (46).
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Table 4. Association of SNPs with mRNA expression levelsa
SNP Position on chrom 4 Gene MAF GWAS ORb SNCA
(probe 29 939)
CTSD
(probe 52 556)
GAK exon 26
(probe 155 700)
GAK exon 28
(probe 397 150)
Beta P-value Beta P-value Beta P-value Beta P-value
rs1564282 842,313 GAK 0.14 (T) 1.7 0.35c 0.003 20.06 0.49 20.12 0.16 20.15 0.03
rs356229 90,825,620 3’ SNCA 0.44 (C) 1.35 20.03 0.70 0.02 0.73 20.01 0.87 20.01 0.83
rs356188 90,910,560 SNCA 0.29 (C) 0.7 20.08 0.27 0.12 0.007 0.11 0.02 0.07 0.1
rs3775478 91,061,863 MMRN1 0.12 (G) 1.7 0.05 0.67 0.04 0.55 20.05 0.53 20.04 0.56
MAF, minor allele frequency; Beta, beta coefficient.
aAdjusted for PD/control, RIN, PMI and age at death.
bOR previously reported for SNPs association to PD in our Familial PD GWAS (7) with P-values ranging from 5.9 × 1026 to 8.4 × 1025.
ceSNP beta estimate in a subset of 32 brain samples with available ethnicity information (all Caucasians) was similar to the beta estimate value in the whole set of
brains (Beta ¼ 0.33).
Figure 1. Potentiation of a-synuclein-mediated toxicity in cell culture systems with reduced GAK expression. (A and B) HEK 293 cells were transiently trans-
fected with CMV-GFP, CMV-a-synuclein and either non-targeted (NT) or GAK-targeted pools of siRNA. (A) Toxicity was assessed by release of adenylate
kinase into the media 72 h after transfection. Enzymatic release was detected by luciferase reaction and quantified by relative luminescent units (RLU) compared
with controls (Toxilight). (B) a-Synuclein protein levels in siRNA-treated cell lysates were quantified by ELISA. (C and D) Primary midbrain cultures were
transduced with A53T adenovirus (MOI ¼ 3) with or without lentivirus encoding either (C) GAK shRNA ‘A’ (MOI ¼ 3) or (D) GAK shRNA ‘B’ (MOI ¼
1). Control cells were incubated in the absence of virus. Dopaminergic cell viability was determined by staining with antibodies specific for MAP2 and TH
and is expressed as the percentage of MAP2-positive neurons that were also TH-positive.
Table 3. Correlation between mRNA expression levels
SNCA (probe 29 939) CTSD (probe 52 556) GAK exon 26 (probe 155 700) GAK exon 28 (probe 397 150)
SNCA 0.10 (0.58) 0.15 (0.42) 20.13 (0.47)
CTSD 0.28 (0.14) 0.45 (0.009) 0.18 (0.31)
GAK exon 26 (probe 155 700) 0.18 (0.34) 0.50 (0.006) 0.79 (,0.0001)
GAK exon 28 (probe 397 150) 20.27 (0.16) 0.02 (0.93) 0.58 (0.001)
Correlations were computed separately for PD cases (above diagonal) and controls (below diagonal). P-values are indicated in parentheses.
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GAK(P ¼ 3.1 × 1024) in a GWAS for 2000 PD cases and
1986 controls from the NeuroGenetics Research Consortium
(NGRC). Thus, while the evidence for GAK SNPs associated
with PD was first seen in a cohort of familial PD (7) and
reported here in the subset of Italian families with family
history of PD, the association of GAK in PD risk appears to
be present in random PD samples as well. Nevertheless, our
results support the power of the familial PD sub-population
in identifying genetic contributors to PD. Our replication
and functional studies further suggest that new pathways
identified in this way will likely prove relevant to the patho-
genesis of idiopathic PD.
We also found that rs1564282 was associated with higher
levels of SNCA expression, as reflected by the mRNA level,
in the total sample of brains, adjusting for case/control
status. Using a stratified analysis, we observed this eSNP
relationship to be stronger in PD (beta ¼ 0.473, P ¼ 0.013),
than in control samples (beta ¼ 0.163, P ¼ 0.267), although
the effect of the SNP on expression is consistent in the two
groups. Altered mRNA levels could be an influence on stab-
ility or degradation of the transcripts, and may not reflect
altered mRNA expression. However, higher SNCA levels are
consistent with the previously reported increased PD risk
observed in duplication and triplication of the SNCA gene, a
rare, but recognized, cause of early-onset PD (37–39). We
examined the expression levels of two C-terminal GAK
exons, exons 26 and 28, in post-mortem brains. Exon 26 is
known to encode part of the clathrin-binding domain of
GAK, which is critically involved in the sorting of the
CTSD pro-enzyme, while exon 28 encodes the J-domain of
the protein (22). We found exon 26 to be correlated with
CTSD exon 6 expression, which was not observed for GAK
Figure 2. Western blot analyses confirming reduced GAK expression and enhanced a-synuclein accumulation. (A) GAK protein levels and (B) a-synuclein
protein levels in HEK 293 cells transfected with either CMV-GFP (lanes 1 and 2) or CMV-a-synuclein (lanes 3 and 4) and non-targeted (lanes 1 and 3) or
GAK-specific (lanes 2 and 4) pools of siRNA’s. Western blot quantifications were performed via densitometric analysis using NIH ImageJ software. GAK
band intensities were normalized first to the GAPDH signal and then to the values for non-targeted, GFP-transfected cells lane (set to 100%) (A), while
a-synuclein band intensities were reported as relative expression levels of a-synuclein compared to GAPDH (B). Each experiment was performed in triplicate.
(C) Representative western blot depicting shRNA-mediated GAK knockdown in the MES23.5 dopaminergic cell line (n ≥ 2 for each of the different treatment
conditions). Lysates were prepared from control cells (lane 1), and cells transduced with A53T-a-synuclein adenovirus alone (lane 2, MOI ¼ 30) or with
A53T-a-synuclein adenovirus (MOI ¼ 30) plus lentivirus encoding GAK-specific shRNA ‘A’ (lane 3, MOI ¼ 30) or ‘B’ (lane 4, MOI ¼ 15). The graph
below the blot shows relative GAK protein levels determined via densitometric analysis using NIH ImageJ software. GAK band intensities were normalized
first to the b-actin signal and then to the normalized GAK band intensity in the control lane (set to 100%). The data suggest that (i) A53T expression
induces GAK downregulation in the MES23.5 dopaminergic cell line, and (ii) shRNAs A and B induce a further decrease in GAK levels in A53T-expressing
cells.
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exon 28. This suggests the presence of alternative splicing of
GAK brain transcripts, whereby transcripts that contain exon
26, but not exon 28, have distinct relationships to CTSD levels.
We evaluated the relationship between expression of GAK
and a-synuclein toxicity in two biological models: (i) a
HEK 293 cell line transiently overexpressing a-synuclein,
and (ii) primary rat neuronal cells transduced with the virus
expressing SNCA with the A53T mutation. In both models,
knockdown of GAK expression resulted in dramatic increases
in cell death. Specifically, in the HEK 293 cells, siRNA
knockdown of GAK increased toxicity and overall a-synuclein
protein levels. In the primary neuronal cultures, expression of
shRNA for GAK reduced the survival of TH+ dopaminergic
neurons relative to that of total (MAP2+) neurons. From
these data we infer that down-regulation of GAK enhances
the preferential toxicity of A53T a-synuclein to dopaminergic
neurons (29–31,40). Interestingly, the substantia nigra
expression study performed by Grunblatt et al. (15) showed
a 1.56-fold increase in GAK expression in PD compared
with control samples. One possible explanation is the presence
of a compensatory effect in the PD-affected brain region,
which would lead to increased GAK expression. The minor
allele of the rs1564282 GAK SNP is nominally associated
with decreased expression of GAK exon 28 in frontal cortex,
and decreased expression of GAK might be a possible mechan-
ism by which this SNP is linked to increased risk for PD.
The described studies implicate GAK, SNCA and CTSD in
PD pathogenesis, suggesting a role for these genes within a
clathrin-mediated endocytic pathway involved in promoting
neuronal toxicity. Additionally, the combination of GAK
knockdown and a-synuclein over-expression may provide
new in vitro models for PD, a disease that has been histori-
cally difficult to model. Finally, while the specific mechan-
isms by which GAK depletion enhances a-synuclein
toxicity are not known, further studies targeted at enhancing
GAK’s function may provide novel approaches for PD
treatment.
MATERIALS AND METHODS
Brain samples and microarray expression data
Brain tissue from the frontal cortex Brodmann 9 area was
obtained from three different brain banks: the Harvard
Brain Tissue Resource Center McLean Hospital, Belmont,
Massachusetts; the Human Brain and Spinal Fluid Resource
Center VA West Los Angeles Healthcare Center, California;
and the Sun Health Research Institute Sun City, Arizona.
Thirty-four PD and 29 control samples were identified to
be the best available group of samples for a microarray
study from an available pool of 118 PD and 87 control
brains. We selected samples for inclusion in the micro-array
by the following four criteria: (i) lack of Alzheimer disease
pathology (specified by available neuropathological reports),
(ii) pH value .6.25, (iii) similar age for PD cases and con-
trols, and (iv) male gender. Total RNA for the 34 PD and 29
control samples was extracted with TRIzol (Invitrogen,
Carlsbad, CA, USA). RNA was purified using the RNeasy
MinElute Cleanup columns (Qiagen Sciences Inc, German-
town, MD, USA) and its quality was assessed with an
Agilent Bioanalyzer Nano Chip (Agilent, Foster City, CA,
USA). Two micrograms of each RNA sample were labeled
and hybridized to the One-Color Agilent 60-mer Whole
Human Genome Microarray at the Microarray Facility of
the Whitehead Institute for Biomedical Research (Cam-
bridge, MA, USA). The dye-normalized and post-surrogate
processed signal for the green channel, gProcessedSignal,
obtained from Agilent’s Feature Extraction Software was
used for downstream analyses. The QC reports for each of
the 63 samples were individually inspected, and no systema-
tic errors were determined for any sample. All the microar-
ray processing analyses were performed in R (http://www.
R-project.org).
To ensure that only the high-quality probes were retained
for analysis, standard exclusion criteria were used as
follows: (i) control probes were removed; (ii) each probe
was flagged for a specific sample if (values explained in the
Agilent Feature Extraction Reference Guide): gIsWellAbo-
veBG equal to 0, gIsFeatNonUnifOL equal to 1, gIsBGNonU-
nifOL equal to 1, gIsFeatPopnOL equal to 1, gIsBGPopnOL
equal to 1, or gIsSaturated equal to 1. If more than 50% of
the PD samples or more than 50% of the control samples
had a specific probe flagged, the respective probe was
removed; (iii) each probe was flagged for a specific sample
if the expression value for the probe was outside the range
for the spike-in controls. A probe was removed if it was
flagged in at least 50% PD cases and 50% controls; in
addition, (iv) each probe was flagged for a specific sample if
its expression was below the median expression value of the
sample. If a probe was flagged in more than 80% cases and
more than 80% controls, the probe was removed. To make
sure we were not removing an excessive number of probes,
we compared the list of genes corresponding to the retained
probes with the list of ubiquitously expressed genes published
by Ramskold et al. (41). 86.98% of the genes determined as
ubiquitously expressed by RNA-Seq in the Ramskold et al.
study were present in our set; we considered this value to be
acceptable. Out of the total 45 015 probes present on the
microarray chips, 22 393 (corresponding to 16 567 genes)
were analyzed.
The expression data for the retained probes of the 63 arrays
were quantile normalized, and the obtained values were ln
(natural logarithm) transformed. Two different probes for
GAK (A_23_P155700, targeting expression of the gene’s exon
26, sequence: TCCTCCAGGTCTGACAAGAAAGGGCCAA
AGACCATTGCAGAGATGAGGAAGCAGGACCTG and
A_24_P397150, targeting expression of the gene’s exon 28,
sequence: CCGTACGAGCAGCACGCCAAGATGATCTT
CATGGAGCTGAATGACGCCTGGTCGGAGTTT) were
available on the microarray chip. One probe was available for
CTSD (A_23_P52556, targeting expression of the gene’s exon
6, sequence: GTATTACAAGGGTTCTCTGTCCTACCTGA
ATGTCACCCGCAAGGCCTACTGGCAGGTCCA). The
SNCA gene was targeted by a single probe (A_23_P29939, tar-
geting the 3′-UTR of the gene, sequence: TGACAGATGTTC
CATCCTGTACAAGTGCTCAGTTCCAATGTGCCCAGTC
ATGACATTTCT), repeated 10 times on the microarray. All
these probes passed our strict filtering criteria. The expression
data for SNCA used in this manuscript is the average value for
the 10 repeated probes.
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Sixty-two out of the 63 microarray samples had an RIN
value above 4.8, and only these 62 samples were analyzed
in the current study (42) (Table 2).
Genotyping
The genotyping in the Milan, Italy cohort and the available
brain samples was performed using the TaqMan technology
implemented on an ABI PRISMw 7900HT Sequence Detec-
tion System (Applied Biosystems, Foster City, CA, USA) in
the Neurogenetics Laboratory at Boston University School
of Medicine. In brains, the GAK SNP rs1564282 and three
SNPs around the SNCA gene on chromosome 4 (Table 4)
were genotyped.
Statistical analysis of SNP data
The rs1564282 SNP genotyping was obtained from three pub-
licly available GWAS data sets available from dbGaP: a
sample of familial PD cases and NINDS controls (all self-
reported white, non-Hispanic and screened for population out-
liers using the multidimensional scaling method; n ¼ 1728,
865 cases, 863 controls) (7), an NIA sponsored case/control
GWA (all self-reported white, non-Hispanic; n ¼ 505, 256
cases, 249 controls) (10) and the second release of publicly
available data from the NIA (all self-reported white, non-
Hispanic; n ¼ 1166, 644 cases, 522 controls) (9). Subjects in
the three GWASs were cleaned with identical QC thresholds,
requiring 98% or higher call rate and screening for sex inconsis-
tency. The rs1564282 SNP met all quality control criteria
including call rate above 98%, consistency with Hardy–Wein-
berg equilibrium (HWE) in controls, and did not appear differ-
entially missing by genotype (the MISHAP test), by case/
control status or by sex. Local genotyping in the Milan, Italy
cohort [all white, non-Hispanic samples; case (n ¼ 862), con-
trols (n ¼ 517)] was also consistent with HWE among controls
and had a 96% call rate. SNP analysis was implemented in
PLINK (43) separately for each of the four cohorts using logistic
regression with adjustment for age (onset for cases/enrollment
for controls) and sex. Meta-analysis was implemented with
METAL using the inverse variance method.
The relationship of SNPs to expression levels (eSNP
studies) was performed using linear regression in SAS v9.1.
The normalized mRNA levels were modeled as the dependent
variable and the association of SNPs was adjusted for PD/
control status, RIN, PMI and age at death. The RIN and pH
were the most highly correlated variables in our data (Spear-
man correlation coefficient ¼ 0.403, P-value ¼ 0.001) and
we decided to include in the linear regression model only
one of these two variables, to avoid the problem of over-
adjustment. We chose the RIN variable, given its larger
range of values compared with pH (Table 2). The results
obtained with pH in the model instead of RIN are very
similar (unreported). SNPs were modeled to estimate the
effect of the minor allele with an additive genetic model
except when fewer than five rare allele homozygotes were
present in the data (corresponding to MAF ≤ 0.14), when a
dominant model was implemented (rs1564282, rs3775478).
Knockdown of GAK in HEK 293 cells, cytotoxicity and
ELISA assays
HEK 293 cells (ATCC) were maintained at 378C, 5% CO2 in
DMEM supplemented with 10% fetal bovine serum (Sigma),
2 mM glutamine, 10 mg/ml penicillin and 10 mg/ml streptomy-
cin (GIBCO). GAK knockdown experiments were conducted
in 96-well plates by siRNA treatment with either
ON-TARGETplus SMART pool L-005005-00-0005, human
GAK or ON-TARGETplus Non-targeting Pool
D-001810-10-05 (Dharmacon/Thermo), as well as plasmids
DNA encoding cytomegalovirus (CMV)-a-synuclein or
CMV-GFP by Lipofectamine 2000. The protocol provided
by the manufacturer was followed for co-transfection of
siRNA and plasmid DNA in 96-well format. Each experiment
had six separate wells per condition and the experiments were
repeated three times. Toxicity was accessed by adenylate
kinase release (ToxiLight, Amaxa) 72 h post-transfection and
subsequent luminescent readings were acquired on a Perkin
Elmer Envision 2103 Multilabel reader. The a-human
a-synuclein ELISA kit was obtained from Invitrogen and the
protocol was described by the manufacturer.
Antibodies
The following antibodies were used in this study: mouse
anti-b-actin (Clone AC-74, Sigma-Aldrich, St Louis, MO,
USA); chicken anti-MAP2 (EnCor Biotechnology); rabbit
anti-TH (Chemicon); mouse anti-GAK (clone 1C2, Medical
and Biological Laboratories); rabbit anti-GAPDH (Abcam);
mouse anti-a-synuclein (BD Biosciences); anti-rabbit
IgG-Alexa Fluor 488 and anti-chicken IgG-Alexa Fluor 594
(Invitrogen) and anti-mouse IgG-conjugated with alkaline
phosphatase (Promega, Madison, WI, USA).
Western blotting
Protein expression levels in MES23.5 cultures were determined
via western blot analysis. The cells were dislodged from the
plate by pipetting, collected by centrifugation, washed with
phosphate-buffered saline (PBS) (136 mM NaCl, 0.268 mM
KCl, 10 mM Na2HPO4, 1.76 mM KH2PO4, pH 7.4), and lysed
in RIPA buffer [25 mM Tris–HCl, pH 7.4, 150 mM NaCl,
1 mM EDTA, 1% (v/v) Triton X-100, 0.1% (v/v) SDS, 1
sodium deoxycholate and protease inhibitor cocktail (Sigma)].
After centrifugation at 13 000g, the detergent-soluble (super-
natant) fraction was recovered. The protein concentration in
the soluble fraction was measured using the bicinchoninic
acid Protein Assay Kit (Pierce Biotechnology, Rockford, IL,
USA), and equal amounts of protein were separated via
sodium dodecyl sulfate polyacrylamide gel electrophoresis on
a 4–20% (w/v) polyacrylamide gel. The proteins were trans-
ferred to a polyvinylidenedifluoride membrane, which was
then probed with a primary antibody specific for GAK
(1:1000). The membrane was treated with a secondary anti-
mouse alkaline phosphatase-conjugated antibody (1:6000).
Chemifluorescence images were obtained and analyzed using
a Typhoon imaging system (GE Health Sciences, Piscataway,
NJ, USA). Densitometry analysis of the western blots was per-
formed using NIH ImageJ software, where targeted proteins
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(GAK or a-synuclein) were compared with house keeping
genes, GAPDH or b-actin.
Preparation of lentiviral constructs
To ensure that changes in dopaminergic cell viability were due
specifically to GAK knockdown and did not result from off-
target effects, we conducted the shRNA experiments using
three different shRNA constructs targeting different regions
of the GAK gene. The use of multiple non-overlapping
shRNAs (‘multiplicity control’) is an acceptable approach to
ensure the validity (specificity) of an RNAi-mediated pheno-
type (44). All three shRNA constructs produced similar
effects on dopaminergic cell viability (the data obtained
using two of these constructs are included here).
The pLenti shRNA constructs targeting rat GAK were pur-
chased from OpenBioSystems. Clone identification numbers
for the two constructs presented in this study are
TRCN0000027669 and TRCN0000027605. These constructs
are referred to here as ‘shRNA A’ and ‘shRNA B’, respect-
ively. The ViraPower Lentivirus Expression System (Invitro-
gen) was used to generate lentivirus encoding rat shRNA
GAK (A or B). Lentiviral constructs were packaged into
viruses as described (31,45). Lentiviral particles were titered
using the Traditional p24 ELISA kit purchased from Cell
Biolabs.
Preparation of adenoviral constructs
The ViraPower Adenovirus Expression System (Invitrogen)
was used to generate adenovirus encoding human
A53T-aSyn (downstream of the CMV promoter) as described
(29,31). Adenoviral constructs were packaged into the virus
via lipid-mediated transient transfection of the 293A packa-
ging cell line. Adenoviral particles were titered using the
QuickTiter Adenovirus Titer ELISA Kit (Cell Biolabs).
Preparation of primary mesencephalic cultures
Primary midbrain cultures were prepared via dissection of day
17 embryos obtained from pregnant Sprague–Dawley rats
(Harlan, Indianapolis, IN, USA) as described previously
(31). All of the procedures involving animal handling were
approved by the Purdue Animal Care and Use Committee.
The cells were plated on poly-L-lysine-treated 48-well plates
at a density of 163 500 cells per well. Five days after
plating, the cells were treated with cytosine arabinofuranoside
(20 mM, 48 h) to inhibit the growth of glial cells. At this stage
(i.e. 7 days in vitro), the glial cells accounted for 50% of the
total cell population, and the neurons appeared differentiated
with extended processes.
Lentiviral and adenoviral transductions
Primary cultures (7 days in vitro) were transduced with lenti-
virus and/or adenovirus in the presence of polybrene (6 mg/
ml). The transductions were carried out for 72 h at a multi-
plicity of infection (MOI) of 3 in the case of A53T adenovirus
and GAK shRNA lentivirus ‘A’, or an MOI of 1 in the case of
GAK shRNA lentivirus ‘B’. The cells were then treated with
fresh media for an additional 24 h and analyzed by immuno-
cytochemistry. Control samples consisted of untransduced
primary rat midbrain cultures (Fig. 1C and D), as well as
primary rat midbrain cultures treated with sub-lethal levels
of the A53T adenovirus and with a non-specific lentivirus
(lenti-LacZ) (data not shown). In addition, the use of multiple
GAK shRNA lentiviruses (multiplicity control) ensured that
the phenotype produced by each shRNA was due to GAK
knockdown rather than non-targeting effects (44). MES23.5
cells were transduced with A53T adenovirus (MOI ¼ 30)
and GAK shRNA lentivirus (MOI ¼ 15 or 30) for 24 h.
After incubating the cells in fresh media for 48 h, lysates
were prepared and analyzed via western blotting.
Immunocytochemistry
Primary cells were fixed, permeabilized and blocked as
described (31,45). After washing with PBS, the cells were
treated overnight at 48C with the primary antibodies
anti-MAP2 (1:1000) and anti-TH (1:500). After washing
with PBS, the cells were treated with goat anti-rabbit Alexa
Fluor 488 and goat anti-chicken Alexa Fluor 594 for 1 h at
room temperature. Prolong gold antifade reagent with DAPI
(Invitrogen) was then applied to each before adding a
cover slip.
Measurement of primary neuron viability
MAP2- and TH-immunoreactive primary neurons were
counted in 10 randomly chosen observation fields (500–
1000 neurons total) for each experimental condition using a
Nikon TE2000-U inverted fluorescence microscope (Nikon
Instruments, Melville, NY, USA) with a 20X objective. The
data were expressed as the percentage of MAP2+ neurons
that were also TH+ (this ratiometric approach was used to
correct for variations in cell density). Each experiment was
repeated three to four times using embryonic neurons isolated
from different pregnant rats. Statistical analyses consisted of
one-way analysis of variance with the Newman–Keuls post
hoc test and were carried out using the program GraphPad
Prism, Version 4.0 (http://www.graphpad.com/prism/Prism.htm).
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